Program Antibody Patents. Subject to Adimab’s rights under Section 5.2(c), neither Party is entitled to practice or license any Program Antibody Patent that is not a Licensed Program Antibody Patent without consent of and without a duty of accounting to the other Party; except that (x) Adimab may practice such Program Antibody Patents within the scope of its license under Section 3.1(b) and (y) Kairos (and others) may practice such Program Antibody Patents within the scope of its license under Section 3.1(a) and covenant not to ▇▇▇ under Section 3.5(b).
Appears in 1 contract
Sources: Collaboration Agreement (Compass Therapeutics, Inc.)
Program Antibody Patents. Subject to Adimab’s rights under Section 5.2(c), neither Party is entitled to practice or license any Program Antibody Patent that is not a Licensed Program Antibody Patent without consent of and without a duty of accounting to the other Party; except that (x) Adimab may practice such Program Antibody Patents within the scope of its license under Section 3.1(b) and (y) Kairos (and others) Arsanis may practice such Program Antibody Patents within the scope of its license under Section 3.1(a) and covenant not to ▇▇▇ under Section 3.5(b).
Appears in 1 contract
Program Antibody Patents. Subject to Adimab’s rights under Section 5.2(c), neither Party is entitled to practice or license any Program Antibody Patent that is not a Licensed Program Antibody Patent without consent of and without a duty of accounting to the other Party; except that (x) Adimab may practice such Program Antibody Patents within the scope of its license under Section 3.1(b) and (y) Kairos Alector (and others) may practice such Program Antibody Patents within the scope of its license under Section 3.1(a) and covenant not to ▇▇▇ under Section 3.5(b).
Appears in 1 contract